
LEO pharma
Develops, manufactures and markets pharmaceutical drugs to dermatologic and thrombotic patients.
- Healthcare
- pharmaceutical
Date | Investors | Amount | Round |
---|---|---|---|
* | €450m | Growth Equity non VC | |
Total Funding | 000k |
EUR | 2017 | 2018 | 2019 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | - | - | - | - | 702 % | (86 %) |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | - | - | - | (49 %) | (39 %) | (32 %) |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
LEO Pharma is a global pharmaceutical company specializing in dermatology, focusing on innovative treatments for skin diseases. The company operates in the healthcare market, primarily serving patients, healthcare professionals, and industry partners. LEO Pharma's business model revolves around research and development, leveraging its Open Innovation platform to collaborate with external partners. This platform allows partners to test proprietary compounds in advanced biological assays at no cost, without business obligations, and with full ownership of the data. The company generates revenue through the development and commercialization of dermatological drugs, as well as through strategic partnerships and collaborations. LEO Pharma's commitment to innovation and collaboration positions it as a leader in the dermatology sector.
Keywords: dermatology, bioassays, open innovation, skin diseases, pharmaceutical, partnerships, R&D, healthcare, drug development, collaboration.
Tech stack
Investments by LEO pharma
Edit
